[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100383897":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Thomas Jefferson University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Iron","ACTIVE_COMPARATOR","325mg oral iron (ferrous sulfate) twice daily",[13],"Drug: Ferrous Sulfate",{"label":15,"type":16,"description":17,"interventionNames":18},"Intravenous Iron","EXPERIMENTAL","510mg ferumoxytol intravenous infusion for two doses total; second dose 3-8 days after first dose.",[19],"Drug: Ferumoxytol",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ferumoxytol","510mg infusion x 2 doses 3-8 days apart",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Ferrous Sulfate","325mg oral twice daily",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Rupsa C Boelig, MD","CONTACT","215-955-9196","rupsa.boelig@jefferson.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Thomas Jefferson University Hospital","RECRUITING","Philadelphia","Pennsylvania","19107","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-75.16362,39.95238,{"lat":50,"lon":49},[53],{"name":33,"role":34,"phone":26,"phoneExt":26,"email":36},{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[57],{"name":58,"class":59},"Auerbach Hematology and Oncology","UNKNOWN","100383897","phase-4-early-antenatal-support-for-iron-deficiency-anemia-100383897",false,"NCT04278651","Early Antenatal Support for Iron Deficiency Anemia","Early Antenatal Support for Iron Deficiency Anemia: A Randomized Controlled Trial of Early Initiation of Intravenous Versus Oral Iron Therapy for Treatment of Iron Deficiency Anemia in Pregnancy","EASI-A","Inclusion Criteria:\n\n* Singleton gestation\n* Gestational age \\\u003C24 weeks\n* Baseline Hb ≥9.0 and \\\u003C11.0 with evidence of iron deficiency anemia\n\nIron deficiency anemia diagnosed (at any point in patient history) by:\n\n* Hb\\\u003C11.0\n* Ferritin\\\u003C30 and\u002For total iron saturation \\\u003C20\n\nExclusion Criteria:\n\n* Sickle cell Disease (NOT sickle cell trait)\n* Evidence of acute anemia requiring transfusion or IV iron therapy\n* Major congenital or chromosomal anomaly\n* Previous use of IV iron in this pregnancy\n* Severe cardiac, renal, or liver disease\n* Autoimmune disease (ie Systemic Lupus Erythematosus (SLE)\n* Allergy or contraindication to either study drug\n* History of medication allergy, reaction to IV infusion, or reaction to Feraheme or other IV iron products","FEMALE","18 Years","65 Years",{"count":72,"type":73},80,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","This is a randomized, controlled multi-site trial of iron therapy in pregnancy. The purpose of this research is to see if second trimester initiation of intravenous (IV) iron therapy is better than oral iron therapy for treatment of anemia in pregnancy by improving blood count, quality of life and reducing side effects.",[79,80,81],"Pregnancy Related","Anemia, Iron Deficiency","Anemia of Pregnancy","2025-11-25",{"date":84,"type":85},"2025-12-02","ACTUAL",{"date":87,"type":85},"2021-09-29",{"date":89,"type":73},"2026-12-30",{"name":5,"class":6},1]